Germany's G-BA Sets Out Financial-Based Criteria For Assessing Drugs Already On The Market
This article was originally published in The Pink Sheet Daily
Germany's senior reimbursement body, the G-BA, has set out criteria – based on the financial success of products – to evaluate drugs already on the market.
You may also be interested in...
Germany’s G-BA has panned Novartis’ Galvus, but retained Merck’s Januvia and Bristol/AstraZeneca’s Onglyza as it starts culling older drugs.
A State Social Court of Berlin-Brandenburg ruling against Novartis means that Germany's reimbursement bodies can move forward with the benefit assessment of older pharmaceutical products.
Novartis essentially makes volume trade-off in the most recent NICE assessment, adding a claim for ages 6-11 but offering pricing concessions as well; if the firm’s experience is any indication, even older products that come under NICE’s cost-effectiveness scrutiny will need discounts and additional data to stay in the authority’s good graces.